Physician profile
Melissa S Davis
NPI 1558557132
$361,690.71
in general payments reported to CMS, 2019-2025
33 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $39K · 2023: $73K · 2024: $111K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Consulting Fee: $63K · Travel and Lodging: $44K · Food and Beverage: $22K · Honoraria: $1,608 · Education: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,356.50 |
| Consulting Fee | $63,194.00 |
| Travel and Lodging | $44,016.69 |
| Food and Beverage | $21,690.19 |
| Honoraria | $1,608.11 |
| Education | $561.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $127,490.61 | 2021-2025 | Olumiant, Ebglyss, Taltz |
| Abbvie INC. | $80,627.39 | 2021-2025 | |
| Janssen Biotech, INC. | $66,547.63 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $30,605.27 | 2023-2025 | Zoryve |
| Ucb, INC. | $19,208.81 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $8,530.81 | 2021-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,198.60 | 2021-2024 | Spevigo, Cyltezo |
| Eli Lilly and Company | $5,150.45 | 2022-2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $4,772.25 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,965.86 | 2021-2025 | Dupixent |
| Lnhc, INC | $1,698.20 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $1,590.84 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $1,531.45 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $1,084.56 | 2021 | |
| Genzyme Corporation | $798.55 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $727.51 | 2023-2024 | Vtama |
| Amgen INC. | $684.13 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $643.36 | 2021-2023 | Klisyri, Seysara |
| Incyte Corporation | $533.08 | 2022-2025 | Opzelura, Opzelura |
| Kowa Pharmaceuticals America, INC. | $350.00 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $256.12 | 2022-2025 | Winlevi, Absorica Ld |
| Janssen Scientific Affairs, LLC | $247.79 | 2024-2025 | Tremfya |
| Pfizer INC. | $149.07 | 2023-2025 | |
| Nobelpharma America, LLC | $73.63 | 2023 | |
| Verrica Pharmaceuticals INC. | $50.09 | 2023 | Ycanth |
| Paratek Pharmaceuticals, INC. | $38.86 | 2024 | Nuzyra |
| Botanix Sb INC | $34.63 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $31.72 | 2022-2023 | Valchlor |
| Sandoz INC. | $19.42 | 2024 | Hyrimoz |
| Sebela Pharmaceuticals INC. | $16.36 | 2023 | Naftin, Pramosone |
| Journey Medical Corporation | $14.30 | 2023 | |
| Nabriva Therapeutics, Plc | $12.61 | 2022 | |
| Organon LLC | $6.75 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.